Şunu aradınız:: sterilis (Portekizce - İngilizce)

avena sterilis
avena sterilis

potentilla sterilis é uma espécie de planta com flor pertencente à família rosaceae.
potentilla sterilis, also called barren strawberry, is a species native to europe.

a mistura de preservação directamente colhida não deve conter avena fatua, avena sterilis nem cuscuta spp.
the directly harvested preservation mixture shall not contain avena fatua, avena sterilis and cuscuta spp.

particularidade para o teor máximo em sementes das espécies avena fatua, avena sterilis, avena ludoviciana e lolium temulentum:
special conditions in respect of the maximum content of seeds of the species avena fatua, avena sterilis, avena ludoviciana and lolium temulentum:

análises genéticas mostram as formas ancestrais de "avena sterilis" cresceu no crescente fértil do oriente médio.
genetic evidence shows the ancestral forms of "a. sterilis" grew in the fertile crescent of the near east.

a contagem das sementes de avena fatua e avena sterilis pode ser dispensada, a não ser que haja dúvida sobre o cumprimento das normas fixadas na coluna 12;
the determination of seeds of avena fatua, and avena sterilis by number need not be carried out unless there is doubt whether the conditions laid down in column 12 have been satisfied;

a presença de uma semente de avena fatua e avena sterilis numa amostra com o peso fixado não é considerada impureza se uma segunda amostra de peso igual ao dobro do fixado não contiver sementes destas espécies;
the presence of one seed of avena fatua, and avena sterilis in a sample of the prescribed weight shall not be regarded as an impurity where a second sample of twice the prescribed weight is free from any seeds of these species;

a presença de uma semente de avena fatua, avena sterilis ou lolium temulentum numa amostra com o peso fixado não será considerada impureza se uma segunda amostra com o mesmo peso estiver isenta de sementes dessas espécies;
the presence of one seed of avena fatua, avena sterilis or lolium temulentum in a sample of the prescribed weight shall not be regarded as an impurity where a second sample of the same weight is free from any seeds of these species;

emea/mb/050/00 relatório anual 2000 page 79/88 medicamento empresa Área terapêutica apresentação emea/cvmp comissão -denom. -nome -espécie -forma -validação -parecer recebido comercial em -dci -origem -indicação -dosagem -parecer -data da decisão -parte a/b -número de -tempo activo -notificação apresentações -tempo inactivo -jornal oficial econor novartis pigs 10%/50% premix -12. 10. 1999 -07. 04. 2000 valnemulin a prevention various -08. 03. 2000 -15. 09. 2000 parte b/treatment of 2 -148 days -22. 09. 2000 (extension) dysentery and -0 -oj c 308, treatment/control of 27. 10. 2000 enzootic pneumonia (qj01xx94) dicural fort cattle pigs solution for injection -16. 12. 1998 -21. 07. 2000 difloxacin dodge antibacterial for 50 mg/ml -21. 06. 2000 -24. 10. 2000 parte b animal systemic use 3 -203 days -25. 10. 2000 (extension) health (qj01ma) -351 days -oj c 337, nl 28. 11. 2000 poulflox virbac poultry oral solution -09. 12. 1999 -21. 07. 2000 difloxacin s. a.antibacterial for 100 mg/ml -21. 06. 2000 -16. 11. 2000 parte b f systemic use 3 -152 days -oj c 2, qj01ma94) -43 days 05. 01. 2001 bayovac csf bayer pigs emulsion for injection -16. 12. 1998 -07. 08. 2000 marker d marker vaccine e2 glycoprotein of -19. 07. 2000 live vaccine against classical classical swine fever -210 days parte a swine fever virus -309 days (qj57ea) 4 porcilis ar-t -intervet pigs suspension for injection -12. 01. 1999 -18. 08. 2000 df internati vaccine against 2 ml -19. 07. 2000 -16. 11. 2000 inactivated onal atrophic rhinitis 2 -204 days -oj c 2, vaccine nl (qj57ea) -336 days 05. 01. 2001 parte a pruban intervet dogs cream -15. 09. 1998 -18. 08. 2000 rescortol internati anti-inflammatory 1 mg/g -19. 07. 2000 -16. 11. 2000 butyrate onal for cutaneous 1 -196 days -oj c 2, parte b nl inflammatory -477 days 05. 01. 2001 disorders (qd07ac90) pirsue pharmaci dairy cattle sterile solution for -12. 01. 1999 -10. 11. 2000 pirlimycin a clinical sub -intramammary use -11. 10. 2000 parte b upojhn clinical mastitis 5 mg/ml -210 days b (qj51ff90) 4 -428 days zubrin schering dogs oral lyophilisate -18. 05. 1999 -08. 12. 2000 tepoxalin -plough treatment of pain 30, 50, 100 200 mg/ml -08. 11. 2000 parte b uk inflammation 39 -210 days -330 days eurican herpes merial dogs powder plus solvent for -13. 07. 1999 -08. 12. 2000 205 f vaccine against emulsion for injection -08. 11. 2000 inactivated canine herpes 1 ml -209 days vaccine 2 -274 days parte bemea/mb/050/00 relatório anual 2000 page 80/88 estabelecimento dos limites máximos de resíduos para substâncias novas substância Área terapêutica emea/cvmp comissão -dci -espécie -validação -enviado à comissão -parecer -data do regulamento -tempo activo -jornal oficial -tempo inactivo bismuth subnitrate bovine -18. 06. 1999 -12. 11. 1999 (extension) -13. 10. 1999 -19. 06. 2000 -113 days -oj l 145, 20. 06. 2000 -0 acetyl isovaleryl porcine -18. 10. 1995 -12. 11. 1999 tylosin tartrate -13. 10. 1999 -19. 06. 2000 -195 days -oj l 145, 20. 06. 2000 -1260 days methylprednisolone bovine -13. 07. 1999 -12. 11. 1999 -13. 10. 1999 -19. 06. 2000 -92 days -oj l 145, 20. 06. 2000 -0 deltamethrin fin fish -09. 12. 1999 -07. 04. 2000 (extension) -08. 03. 2000 -15. 09. 2000 -90 days -oj l 234, 16. 09. 2000 -0 tylosin eggs -09. 11. 1999 -07. 04. 2000 (extension) -08. 03. 2000 -15. 09. 2000 -90 days -oj l 234, 16. 09. 2000 -0 dicyclanil ovine -25. 02. 1997 -07. 04. 2000 -08. 03. 2000 -15. 09. 2000 -281 days -oj l 234, 16. 09. 2000 -825 days tilmicosin rabbit -16. 07. 1999 -12. 11. 1999 (extension) -13. 10. 1999 -20. 10. 2000 -86 days -oj l 269, 21. 10. 2000 -0 flumequine bovine milk turkey -27. 07. 1999 -09. 12. 1999 (extension) -10. 11. 1999 -20. 10. 2000 -89 days -oj l 269, 21. 10. 2000 -0 tiamulin rabbit -14. 10. 1999 -11. 02. 2000 (extension) -12. 01. 2000 -20. 10. 2000 -90 days -oj l 269, 21. 10. 2000 -0 dicyclanil sheep fat -23. 02. 2000 -16. 06. 2000 (modification) -17. 05. 2000 -27. 10. 2000 -84 days -oj l 276, 28. 10. 2000 -0 butafosfan dairy cattle -19. 01. 2000 -19. 05. 2000 (extension) -19. 04. 2000 -27. 10. 2000 -90 days -oj l 276, 28. 10. 2000 -0 tilmicosin bovine milk -22. 02. 1999 -19. 05. 2000 (extension) -19. 04. 2000 -27. 10. 2000 -203 days -oj l 276, 28. 10. 2000 -210 days phoxim ovine -19. 01. 2000 -19. 05. 2000 (extension) -19. 04. 2000 -27. 10. 2000 -90 -oj l 276, 28. 10. 2000 -0 flumethrin ovine -19. 01. 2000 -19. 05. 2000 (extension) -19. 04. 2000 -27. 10. 2000 -90 days -oj l 276, 28. 10. 2000 -0 flunixin equine -23. 03. 2000 -21. 07. 2000 (extension) -21. 06. 2000 -29. 12. 2000 -90 days -oj l 336, 30. 12. 2000 -0emea/mb/050/00 relatório anual 2000 page 81/88 substância Área terapêutica emea/cvmp comissão -dci -espécie -validação -enviado à comissão -parecer -data do regulamento -tempo activo -jornal oficial -tempo inactivo toltrazuril porcine -16. 02. 1999 -21. 07. 2000 (extension) -21. 06. 2000 -29. 12. 2000 -206 days -oj l 336, 30. 12. 2000 -284 days thiamphenicol porcine, ovine, turkey, -15. 05. 1998 -08. 11. 2000 (extension) fish -21. 06. 2000 -206 days -562 days difloxacin bovine, porcine -14. 07. 1998 -21. 07. 2000 (extension) -21. 06. 2000 -29. 12. 2000 -205 days -oj l 336, 30. 12. 2000 -503 days halofuginone bovine -10. 12. 1996 -21. 07. 2000 -21. 06. 2000 -29. 12. 2000 -281 days -oj l 336, 30. 12. 2000 -1008 days linear dodecyl bovine -22. 01. 1999 -18. 08. 2000 benzene sulfonic acid -19. 07. 2000 -195 days -321 days phoxim ovine -19. 01. 2000 -18. 08. 2000 (extension) -19. 07. 2000 -120 days -o acetyl isovaleryl porcine -18. 01. 1995 -18. 02. 2000 tylosin tartrate -13. 09. 2000 -274 days -1790 days florfenicol fish -29. 01. 1996 -08. 11. 2000 (extension) -11. 11. 2000 -212 days -1504 days meloxicam porcine -07. 09. 2000 -04. 01. 2001 (extension) -06. 12. 2000 -90 days -0 days tilmicosin turkey -07. 09. 2000 -04. 01. 2001 z( extension) -06. 12. 2000 -90 days -0 daysemea/mb/050/00 relatório anual 2000 page 82/88 anexo 10 pareceres do comp sobre medicamentos órfãos emitidos em 2000 medicamento patrocinador indicação emea/cpmp comissão -apresentação -parecer recebido em -validação -data da designação -parecer -tempo activo somatropin ares-serono aids-wasting -28. 04. 2000 -17. 07. 2000 (europe) ltd -15. 06. 2000 -08. 08. 2000 -11. 07. 2000 -27 days treatment of fabry disease alpha -tkt europe-5s -03. 05. 2000 -17. 07. 2000 galactosidase a ab -15. 06. 2000 -08. 08. 2000 -11. 07. 2000 -27 days alpha -genzyme bv treatment of fabry disease -12. 05. 2000 -17. 07. 2000 galactosidase a -15. 06. 2000 -08. 08. 2000 -11. 07. 2000 -27 days fluorouracil treatment of glioblastoma ethypharm s. a. -26. 05. 2000 -18. 09. 2000 -31. 07. 2000 -18. 10. 2000 -13. 09. 2000 -45 days gemtuzumab wyeth-ayerst treament of acute myeloid leukaemia -07. 06. 2000 -18. 09. 2000 ozogamicin research -31. 07. 2000 -18. 10. 2000 -13. 09. 2000 -45 days 1, 5 -(butylimino) -oxford treatment of gaucher disease -07. 06. 2000 -18. 09. 2000 1, 5-dideoxy, d -glycosciences -31. 07. 2000 -18. 10. 2000 glucitol ltd -13. 09. 2000 -45 days n-carbamyl-l -orphan europe treatment of n-acetylglutamate synthetase -02. 05. 2000 -18. 09. 2000 glutamic acid sarl (nags) deficiency -31. 07. 2000 -18. 10. 2000 -13. 09. 2000 -45 days arsenic trioxide voisin consulting treatment of acute promyelocytic leukaemia -08. 05. 2000 -18. 09. 2000 sarl -15. 06. 2000 -18. 10. 2000 -13. 09. 2000 -90 days thalidomide laboratoires treatment of erythema nodosum leprosum or -01. 06. 2000 -6. 11. 2000 laphal type ii reactions in hansen" s disease -25. 08. 2000 -29. 12. 2000 -27. 10. 2000 -64 days anagrelide shire treatment of essential thrombocythaemia -31. 05. 2000 -6. 11. 2000 hydrochloride pharmaceutical -31. 07. 2000 -29. 12. 2000 development ltd -27. 10. 2000 -89 days busulfan pierre fabre intravenous conditioning treatment prior to -09. 06. 2000 -6. 11. 2000 (intravenous use) médicament hematopoietic progenitor cell transplantation -31. 07. 2000 -29. 12. 2000 -27. 10. 2000 -89 days nitisinone swedish orphan treatment of tyrosinaemia type 1 -05. 06. 2000 -6. 11. 2000 ab -25. 08. 2000 -29. 12. 2000 -27. 10. 2000 -64 days treatment of huntington" s disease ethyl laxdale ltd -05. 06. 2000 -6. 11. 2000 eicosopentaenoate -31. 07. 2000 -29. 12. 2000 -27. 10. 2000 -89 days iloprost schering ag treatment of primary and of the following -10. 05. 2000 -6. 11. 2000 forms of secondary pulmonary hypertension: -31. 07. 2000 -29. 12. 2000 connective tissue disease pulmonary -27. 10. 2000 hypertension, drug-induced pulmonary -89 days hypertension, portopulmonary hypertension, pulmonary hypertension associated with congenital heart disease and chronic thromboembolic pulmonary hypertension...treatment of amyotrophic lateral sclerosis... -07. 08. 2000 --25. 08. 2000 -21. 11. 2000 -89 days
ovineequineporcineporcine, ovine, turkey, fishbovine, porcinebovinebovineovineporcinefishporcineturkeyemea/cvmp -validation -opinion -active time -clockstop -19.01.2000 -19.04.2000 -90 days -0 -23.03.2000 -21.06.2000 -90 days -0 -16.02.1999 -21.06.2000 -206 days -284 days -15.05.1998 -21.06.2000 -206 days -562 days -14.07.1998 -21.06.2000 -205 days -503 days -10.12.1996 -21.06.2000 -281 days -1008 days -22.01.1999 -19.07.2000 -195 days -321 days -19.01.2000 -19.07.2000 -120 days -0 -18.01.1995 -13.09.2000 -274 days -1790 days -29.01.1996 -11.11.2000 -212 days -1504 days -07.09.2000 -06.12.2000 -90 days -0 days -07.09.2000 -06.12.2000 -90 days -0 dayscommission -sent to commission -date of regulation -official journal-19.05.2000 -27.10.2000 -oj l 276, 28.10.2000-21.07.2000 -29.12.2000 -oj l 336, 30.12.2000-21.07.2000 -29.12.2000 -oj l 336, 30.12.2000-08.11.2000-21.07.2000 -29.12.2000 -oj l 336, 30.12.2000-21.07.2000 -29.12.2000 -oj l 336, 30.12.2000-18.08.2000-18.08.2000-18.02.2000-08.11.2000-04.01.2001-04.01.200181annex 10:comp opinions in 2000 on orphan medicinal productsproductsponsorindicationemea/comp -submission -validation -opinion -active timecommission -opinion received -date of designationsomatropinalpha-galactosidase aalpha-galactosidase afluorouracilgemtuzumab ozogamicin1,5-(butylimino)-1,5-dideoxy, d-glucitoln-carbamyl-l-glutamic acidarsenic trioxideares-serono (europe) ltdtkt europe-5s abgenzyme bvethypharm s. a.wyeth-ayerst researchoxford glycosciences ltdorphan europe sarlvoisin consulting sarlaids-wastingtreatment of fabry diseasetreatment of fabry diseasetreatment of glioblastomatreament of acute myeloid leukaemiatreatment of gaucher diseasetreatment of n-acetylglutamate synthetase (nags) deficiencytreatment of acute promyelocytic leukaemia-28.04.2000 -15.06.2000 -11.07.2000 -27 days-03.05.2000 -15.06.2000 -11.07.2000 -27 days-12.05.2000 -15.06.2000 -11.07.2000 -27 days-26.05.2000 -31.07.2000 -13.09.2000 -45 days-07.06.2000 -31.07.2000 -13.09.2000 -45 days-07.06.2000 -31.07.2000 -13.09.2000 -45 days-02.05.2000 -31.07.2000 -13.09.2000 -45 days-08.05.2000 -15.06.2000 -13.09.2000 -90 days-17.07.2000 -08.08.2000-17.07.2000 -08.08.2000-17.07.2000 -08.08.2000-18.09.2000 -18.10.2000-18.09.2000 -18.10.2000-18.09.2000 -18.10.2000-18.09.2000 -18.10.2000-18.09.2000 -18.10.2000thalidomidelaboratoires laphaltreatment of erythema nodosum leprosum or type ii reactions in hansen 's disease-01.06.2000 -25.08.2000 -27.10.2000 -64 days-6.11.2000 -29.12.200082anagrelide hydrochloridebusulfan (intravenous use)nitisinoneshire pharmaceutical development ltdpierre fabre médicamentswedish orphan abtreatment of essential thrombocythaemiaintravenous conditioning treatment prior to hematopoietic progenitor cell transplantationtreatment of tyrosinaemia type 1-31.05.2000 -31.07.2000 -27.10.2000 -89 days-09.06.2000 -31.07.2000 -27.10.2000 -89 days-05.06.2000 -25.08.2000 -27.10.2000 -64 days-6.11.2000 -29.12.2000-6.11.2000 -29.12.2000-6.11.2000 -29.12.2000emea general report 2000productsponsorindicationemea/comp -submission -validation -opinion -active timecommission -opinion received -date of designationethyl eicosopentaenoateiloprost------------emea general reportlaxdale ltdschering ag------------2000